This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 07
  • /
  • Success in Phase III SINGLE trial of Dolutegravir
Drug news

Success in Phase III SINGLE trial of Dolutegravir

Read time: 1 mins
Last updated:14th Jul 2012
Published:14th Jul 2012
Source: Pharmawand
Interim results from the Phase III SINGLE study involving dolutegravir from Shionogi-Viiv HealthCare,demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla. At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50 copies ml) vs. 81% of participants on the single tablet regimen atripla: the difference in the primary endpoint was statistically significant. differences in efficacy were primarily driven by a higher rate of discontinuation due to adverse events on the atripla arm.>

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.